Thiotepa-Based High-Dose Chemotherapy With Autologous Stem-Cell Rescue in Patients With Recurrent or Progressive CNS Germ Cell Tumors Patients with advanced malignancy (N = 385) were randomly assigned ...

For people with cancer, the oral blood thinner apixaban is at least as effective as dalteparin, a low molecular weight heparin given by injection, in preventing a repeat venous thromboembolism (VTE), ...

Results of a study comparing apixaban with low-molecular-weight heparin as a treatment to prevent recurrent blood clots in patients with cancer may assuage some of the concern about the bleeding risk ...

Rockville, MD - The Food and Drug Administration has approved the prophylactic use of dalteparin (Fragmin ®, Pfizer) for venous thromboembolism (VTE) in acutely ill patients with severely restricted ...

Please provide your email address to receive an email when new articles are posted on . Treatment of venous thromboembolism with oral apixaban was noninferior to subcutaneous dalteparin, without ...

Thromboembol in blood vessel. Clot formation, 3D illustration Researchers sought to compare oral apixaban and subcutaneous dalteparin for treating patients with cancer-related venous thromboembolism.

The introduction of low-molecular-weight heparins (LMWHs) was a watershed event in the treatment of thrombotic disorders. LMWHs differ from unfractionated heparin (UFH) in that they have excellent ...

The FDA has approved Fragmin, a low molecular weight heparin, for the treatment of symptomatic venous thromboembolism to reduce the recurrence of VTE in pediatric patients 1 month of age and older.

The US Food and Drug Administration has approved dalteparin sodium (Fragmin; Pfizer) as the first anticoagulant indicated for use in pediatric patients older than 1 month to reduce the risk of ...